πŸ‡ΊπŸ‡Έ FDA
Patent

US 11246881

Nanoparticle to target cancer

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 11246881 (Nanoparticle to target cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K31/7088, A61K31/713, A61K47/10, A61K47/183